AbbVie's Mavyret Gains FDA Approval for Acute Hepatitis C Treatment AbbVie has received FDA approval for Mavyret, the first and only treatment for acute Hepatitis C patients, allowing immediate intervention upon diagnosis.

AbbVie's Mavyret Gains FDA Approval for Acute Hepatitis C Treatment #United_States #AbbVie #MAVYRET #Hepatitis_C #North_Chicago,_Illinois

AbbVie's MAVYRET® Gains FDA Approval for Acute Hepatitis C Treatment AbbVie’s MAVYRET® becomes the first eight-week treatment for acute hepatitis C, paving the way for better patient outcomes and disease management.

AbbVie's MAVYRET® Gains FDA Approval for Acute Hepatitis C Treatment #United_States #AbbVie #North_Chicago #MAVYRET #Hepatitis_C

@HepDART @norahterrault @KeckMedUSC preemptive strategy of giving one week of #mavyret and #zetia seems to prevent development of #HCV after transplant in organs other than liver #hepdart

@EASLnews @EASLedu PGC: Prof. Hezode highlights one of the last frontier of #HCV therapy: the compensated, cirrhotic GT3, rx experienced patient. #Vosevi 12 weeks or #mavyret 16 weeks increases the cure rate to high 90% #ilc2018

#mavyret does not need to be dose adjusted for kidney dz or hemodialysis . Cannot be given to people with advanced #HCV cirrhosis

#mavyret FDA approved for 8 wks across all #HCV genotypes in naive non cirrhotics. Also for those who failed NS5a or NS3/4a DAAs